Meagan Ryan
Senior Scientist Biology & Translational Sciences Nested Therapeutics
Seminars
Tuesday 16th September 2025
Panel Discussion: Identifying the Right Combination for Different Cancers by Tailoring RAS Inhibitors for Tumor-Specific Reponses
11:30 am
- Overcoming the complexity of tumor biology and multiple signaling pathways to select the optimal combination approach for different cancer types
- How can patient-specific genetic profiles and tumor microenvironment data inform the design of more effective combination therapies?
- How do RAS inhibitors alter the tumor microenvironment and improve response to current standard of care cancer treatments?
Tuesday 16th September 2025
Optimizing Combination Strategies for Effective Inhibition of the MAPK Pathway in RAS-Driven Cancers
9:30 am
- Downstream alterations in the RAS MAPK pathway drive resistance to RAS inhibitors in the clinic
- NST-628 is a highly efficacious non-degrading pan-RAF-MEK molecular glue with broad activity in RAS-mutant cancers
- NST-628 is a promising combination anchor in KRAS-mutant cancers
